Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease
A pharmaceutical composition containing hyaluronic acid and mesenchymal stem cells and its use in treating cartilage damage-associated diseases are disclosed. Compared to when hyaluronic acid and mesenchymal stem cells are administered as a mixture, administering mesenchymal stem cells after first administering hyaluronic acid may exhibit superior effects in alleviating disease symptoms in joint tissues affected by arthritis and also decrease the load on knees due to body weight. Accordingly, the pharmaceutical composition may be beneficially used in the treatment of cartilage damage-associated diseases.
1 . A method for treating a subject with a cartilage damage-associated disease, comprising steps of:
(i) administering a first composition that is a hyaluronic acid solution consisting of hyaluronic acid, a salt thereof, or a derivative thereof, dissolved in a physiological saline, phosphate buffered saline, or a biocompatible saline, to the subject; and
(ii) administering a second composition comprising mesenchymal stem cells to the subject, at an interval of 1 hour to 48 hours after step (i),
thereby treating the cartilage damage-associated disease,
wherein the mesenchymal stem cells of step (ii) are derived from umbilical cord blood,
wherein the hyaluronic acid solution of step (i) has a concentration of 0.5% (w/v) to 1% (w/v) of hyaluronic acid, a salt thereof, or a derivative thereof,
wherein the administration of the first and second compositions increases bone trabecular number and decreases bone trabecular separation in the subject,
wherein the first composition is an injection formulation of hyaluronic acid solution, and
wherein the second composition of step (ii) is an injection formulation of mesenchymal stem cell solution, is free from hyaluronic acid, prepared as a separate formulation from the hyaluronic acid solution by suspending mesenchymal stem cells in physiological saline, phosphate buffered saline, biocompatible saline, or culture medium.
2 . The method of claim 1 , wherein the mesenchymal stem cells are contained in an amount of 1.0×10 5 cells/ml to 1.0×10 8 cells/ml of the second composition.
3 . The method of claim 1 , wherein the first composition is administered at a dose of 0.5 to 1.0 mg/kg, body weight and the second composition is administered at a dose of 5×10 4 cells/kg to 1×10 6 cells/kg body weight.
4 . The method of claim 1 , wherein the cartilage damage-associated disease is osteoarthritis, meniscus tear, arthrosis deformans, or chondromalacia.
5 . The method of claim 1 , wherein a site of the subject where the osteoarthritis occurs is jaw joint, shoulder joint, elbow joint, wrist joint, finger joint, spine joint, hip joint, knee joint, ankle joint, or toe joint.
6 . The method of claim 5 , wherein the first composition is administered to the site at a dose of 0.5 to 1.0 mg/kg body weight, and the second composition is administered at a dose of 2×10 6 cells to 1×10 8 cells.
7 . The method of claim 1 , wherein the first and the second compositions are administered intraarticularly.
8 . The method of claim 1 , wherein the interval is 3 hours to 36 hours.
9 . The method of claim 1 , wherein the interval is 6 hours to 24 hours.
10 . The method of claim 1 , wherein the interval is 9 hours to 12 hours.